| 背景 | This product is a recombinant mouse CD16-2 (Fc-gamma receptor IV / FcgammaRIV; UniProt A0A0B4J1G0, gene Fcgr4) protein produced in human embryonic kidney (HEK) 293 cells, corresponding to the receptor ectodomain. Mammalian HEK293 expression supports appropriate folding and glycosylation, which is important for reproducing native IgG-binding behaviour in vitro. The protein is validated for SPR, BLI and ELISA, making it well suited to Fc-receptor binding characterisation, affinity/kinetics ranking of antibody variants, and Fc-engineering workflows. Supplied as an in vivo grade, ultra-low endotoxin preparation (typically less than 0.5 EU/mg), it minimises endotoxin-driven artefacts in sensitive cell-based and functional assays and is available in bulk milligram to gram quantities for screening campaigns and assay standardisation. It is provided for research use only (RUO). As a soluble recombinant receptor rather than an antibody, it is intended as an in-vitro binding reagent and analyte/ligand, not for administration to animals.
Mouse CD16-2, encoded by Fcgr4 and also known as Fc-gamma receptor IV (FcgammaRIV), is a low-to-intermediate-affinity activating IgG Fc receptor of the immunoglobulin superfamily. It is expressed on myeloid cells (monocytes, macrophages, dendritic cells and neutrophils) and is largely absent from lymphocytes. It preferentially binds mouse IgG2a and IgG2b and signals through association with the ITAM-bearing FcR gamma-chain, coupling antibody-opsonised targets to effector programs. Functionally it drives antibody-dependent cellular cytotoxicity and phagocytosis, immune-complex handling, and inflammatory responses, and can enhance antigen presentation by routing immune complexes into MHC pathways. FcgammaRIV shows notably increased activity toward afucosylated IgG. Because it is a key activating receptor, it is widely studied as a determinant of therapeutic antibody effector function. |
|---|
